Back

New horizons in transthyretin cardiac amyloidosis therapy: A systematic review and meta-analysis of sodium-glucose cotransporter 2 inhibitors efficacy

31 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Multidisciplinary approach to heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Melissa Chacon Quiros

Hospital Internacional La Católica, San Jose (Costa Rica)

6 More presentations in this session

Presentation thumbnail
Guideline-directed medical therapy presciption after acute heart failure hospitalization in Japan
Mr K. Kanaoka (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Effects of early empagliflozin in acute decompensated HFrEF on ventricular systolic and diastolic parameters: interaction with endothelial function and arterial stiffness
Doctor O. Katsarou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Off-label low-dose therapy in heart failure reduced ejection fraction: can we achieve the benefits of the four pillars?
Doctor M. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Cardiovascular effects of preferred HOMe-based EXercise training and extended adherence measures in systolic heart failure
Doctor M. Bahls (Greifswald, DE)
Abstract Slides Video
Presentation thumbnail
Innovative strategies and long-term outcomes in left ventricular assist devices therapy for advanced heart failure
Doctor N. Schaeffer (New York City, US)
Abstract Slides Video

Access the full session

Session thumbnail
Multidisciplinary approach to heart failure

The Event

Event poster

ESC Congress 2025

31 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy
thumbnail
Congress Presentation
SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy
thumbnail
Congress Presentation
Impact of sodium-glucose co-transporter inhibitors in mortality and decongestion in cardiac amyloidosis: A systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources